Clinical Report: Elevated Secretory IgA Against Nucleocapsid in Post-COVID Syndrome
Overview
This study identifies elevated levels of secretory IgA against the Nucleocapsid protein and reduced complement component C3 in patients with post-COVID syndrome. These findings suggest potential biomarkers for post-COVID syndrome and highlight the role of the complement system in its pathophysiology.
Background
Post-COVID syndrome poses a significant global health challenge, affecting millions with persistent symptoms following COVID-19 infection. Understanding the immune dysregulation, particularly the roles of antibodies and the complement system, is crucial for developing targeted therapies and improving patient outcomes. This study contributes to the growing body of evidence regarding immune responses in post-COVID syndrome.
Data Highlights
Parameter
Post-COVID Syndrome
COVID-Recovered Controls
Anti-Nucleocapsid sIgA
Increased
Normal
C3 Levels
Reduced
Normal
C4 Levels
Decreased
Normal
CH50
Similar
Similar
Key Findings
Elevated anti-Nucleocapsid sIgA levels were observed in post-COVID syndrome patients.
Reduced C3 levels may indicate ongoing complement activation and consumption.
No significant differences were found in circulating immune complexes between groups.
Anti-Nucleocapsid IgG levels negatively correlated with factor H and CH50 in reinfected vaccinated patients.
Combining anti-Nucleocapsid sIgA and C3 levels improved discrimination between patients and controls.
Clinical Implications
The findings suggest that measuring salivary anti-Nucleocapsid IgA and complement component C3 may serve as useful biomarkers for diagnosing post-COVID syndrome. Clinicians should consider these parameters when evaluating patients with persistent symptoms following COVID-19 infection.
Conclusion
This study highlights the potential of salivary anti-Nucleocapsid IgA and complement dysregulation as biomarkers for post-COVID syndrome, warranting further investigation in larger cohorts.
by Zhiwen Hai, Weihua Yang, Azam Ghazi, Amalia Buitrago, Patricia Marín-García, Isabel G Azcárate, Alba González-Escalada, Nineth Rossi, Javier Benítez-Cruz, Iván Estévez-Benito, Agustín Tortajada, José R. Regueiro, José M. Bautista, Narcisa Martinez-Quiles
Investigative report cites internal communications, VAERS data, and CDC case reviews describing myocarditis and pericarditis reports in adolescents and young adults after mRNA COVID-19 vaccination.
